BlackRock’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

BlackRock’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,565,869	Closed	-$467K	–	5623
2023 Q2	$467K	Sell	1,565,869 -3,394,179	-68%	-$1.02M	﹤0.01%	4499
2023 Q1	$2.14M	Sell	4,960,048 -344,108	-6%	-$264K	﹤0.01%	4028
2022 Q4	$6.26M	Buy	5,304,156 +1,524,735	+40%	+$2.48M	﹤0.01%	3623
2022 Q3	$8.77M	Buy	3,779,421 +2,255,590	+148%	+$5.91M	﹤0.01%	3498
2022 Q2	$3.37M	Buy	1,523,831 +665,044	+77%	+$4.61M	﹤0.01%	3995
2022 Q1	$8.27M	Buy	+858,787	New	+$7.7M	﹤0.01%	3681

BlackRock's GRNA Position: Q3 2023 in Review

BlackRock sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 1,565,869 shares — an estimated $467K sold.

BlackRock first reported a position in GRNA in Q1 2022 and held it in 6 quarters. The position peaked at $8.77M in Q3 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

BlackRock reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
BlackRock sold 1,565,869 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $467K.
BlackRock first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 6 quarters.
BlackRock's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $8.77M in Q3 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.